Lista de obras - A Musolino - Dominio Público Uruguay

A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes

artículo científico publicado en 2005

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

artículo científico publicado en 2020

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

artículo científico publicado en 2017

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2010

Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.

artículo científico publicado en 2017

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

artículo científico publicado en 2019

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

artículo científico publicado en 2014

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

artículo científico publicado en 2007

Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer.

artículo científico publicado en 2016

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

artículo científico publicado en 2018

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

artículo científico

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity

scientific article published on 01 April 2006

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

scientific article published on 07 August 2018

FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.

artículo científico publicado en 2016

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

artículo científico publicado en 2020

Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study

scientific article published on 14 May 2012

Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.

artículo científico publicado en 2009

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

artículo científico publicado en 2008

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.

artículo científico publicado en 2016

Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia

scientific article published on 01 May 2007

Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma

artículo científico publicado en 2005

Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role?

artículo científico publicado en 2005

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review

artículo científico publicado en 2019

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

artículo científico publicado en 2019

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

artículo científico publicado en 2010

My best choice after a round trip from illness

scientific article published on 23 August 2017

Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.

artículo científico publicado en 2017

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

scientific article published on 01 December 2018

PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype

artículo científico publicado en 2020

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

artículo científico publicado en 2017

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

artículo científico publicado en 2012

Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors.

artículo científico publicado en 2017

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

artículo científico publicado en 2017

Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers

artículo científico publicado en 2015

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

artículo científico publicado en 2015

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.

artículo científico publicado en 2013

Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review

artículo científico publicado en 2020

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.

artículo científico publicado en 2013

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

scientific article published on 21 November 2019

p73 and p53 pathway in human breast cancers

scientific article published on 01 April 2007

Lista de obras de A Musolino

A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer.

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study

Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.

Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia

Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma

Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role?

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

My best choice after a round trip from illness

Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors.

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.

Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

p73 and p53 pathway in human breast cancers